Retatrutide

What it is

Retatrutide is the most powerful metabolic peptide in clinical development, and it earns that title with a genuinely new mechanism. Where semaglutide hits one receptor and tirzepatide hits two, retatrutide is the first molecule to activate three at once: GLP-1, GIP, and glucagon. Two of those receptors turn calories-in down; the third turns calories-out up. That third lever — the glucagon arm — is why retatrutide does something the earlier drugs can’t.

If you’ve watched a GLP-1 plateau in yourself or someone you know — fast progress for nine months, then the scale freezes and the cravings creep back — retatrutide is the answer the field built for exactly that wall. In the pivotal Phase 2 obesity trial, people losing weight without dieting or structured exercise still dropped up to 24.2% of body weight at 48 weeks [PMID 37366315]. That is the largest weight-loss effect ever recorded for a non-surgical agent, and the curve doesn’t flatten the way the earlier drugs’ curves do.

This is a tool, and it’s a remarkable one. Used well — with protein, resistance training, and intelligent dosing — it’s a metabolic reset that can move markers most people thought required surgery. The rest of this article gives you what you need to use it well.

How it works

Three receptors, three jobs:

GLP-1 receptor: satiety + glucose. Same target as semaglutide. In the brain it lowers appetite and slows gastric emptying (food sits longer, you feel full sooner, you eat less); in the pancreas it amplifies glucose-dependent insulin release [PMID 41054801].

GIP receptor: fat handling + insulin sensitivity. Tirzepatide’s added receptor. GIP improves how fat tissue stores and releases energy and supports adipocyte function — part of why dual and triple agonists out-body-comp the pure GLP-1 drugs [PMID 41054801].

Glucagon receptor: energy expenditure, the new lever. This is where retatrutide breaks from the pack. Glucagon agonism in the liver and brown fat raises energy expenditure and drives fat oxidation rather than just suppressing intake — your body burns more, not only eats less. As clinician-educators Williams and Froese both describe it: the glucagon arm increases resting energy expenditure, suppresses de-novo lipogenesis (new fat made from carbs), and directly burns liver fat. Normally glucagon would raise blood sugar, but the GLP-1/GIP arms keep insulin secretion robust, so the fat-burning effect runs largely unopposed.

That third receptor is the answer to “why does this break the plateau.” On pure GLP-1 drugs, part of the plateau is your body downshifting its metabolic rate to defend the calorie deficit. The glucagon agonist counters that downshift. Mechanistically, β-hydroxybutyrate rose 2–3 fold (dose-related, without ketoacidosis) in the MASLD trial — a fingerprint of your body shifting to burning fat for fuel (Nature Medicine 2024, PMC11271400).

What the research shows

Retatrutide has unusually strong human evidence for an investigational compound — the base is dominated by randomized trials and RCT-pooled meta-analyses, a far better profile than most peptides in this space.

Human RCT: strongest first:

• Phase 3 TRIUMPH program (topline, company-reported Dec 2025 – May 2026; full publications pending:). TRIUMPH-1, the pivotal general-obesity trial (80 wk; adults with obesity/overweight without T2D), reported mean weight loss of −19.0% (4 mg), −25.9% (9 mg), and −28.3% (12 mg) — and 45.3% of the 12 mg group lost ≥30%, bariatric-surgery territory — with a BMI ≥35 extension reaching −30.3% (~85 lb) at 104 weeks. TRIUMPH-4 (68 wk, n=445, the knee-osteoarthritis + obesity trial, NCT05931367) reported up to −28.7% weight loss and was the first Phase 3 readout (Dec 2025). TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obstructive sleep apnea) round out the >5,800-participant program; TRIUMPH-1 is the trial carrying the weight-management NDA. These are topline figures from Lilly investor/conference releases — pin the full peer-reviewed publications before any customer-facing use.
• Phase 3 TRIUMPH-4: knee osteoarthritis (topline, design paper PMID 41090431, DOI 10.1111/dom.70209; full efficacy publication pending). In adults with BMI ≥27 and knee OA (no T2D), retatrutide met both primary endpoints: alongside the −28.7% weight loss, the 12 mg arm cut WOMAC knee-pain scores by 75.8% (mean −4.5 points), with 12.0% of the 12 mg group completely pain-free vs 4.2% on placebo and more than half hitting the ≥50%-pain-reduction secondary endpoint. This is the first Phase-3-grade evidence that the weight loss translates into a measurable joint-function/recovery benefit — the basis for retatrutide’s secondary heal-recover relevance (weight offloading + the GLP-1 anti-inflammatory signal). Verified against primary sources.
• Phase 2 obesity RCT (Jastreboff/NEJM 2023, n=338) [PMID 37366315] — at 48 weeks, least-squares mean weight change was −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% (12 mg) vs −2.1% placebo. At 12 mg, 100% lost ≥5%, 93% lost ≥10%, 83% lost ≥15%. GI events were dose-related and mostly mild-to-moderate; lower starting doses mitigated them.
• Phase 2 T2D RCT (Rosenstock/Lancet 2023, n=281) [PMID 37385280]: retatrutide produced dose-dependent HbA1c reductions and weight loss in type-2 diabetes. The active comparator in this trial was dulaglutide, not metformin — worth stating plainly, because the popular “67% reached HbA1c <5.7% on retatrutide vs 18% on metformin” framing misattributes the comparator (citation-verification pass 0018); anchor any T2D/glucose claim to this trial, not a metformin head-to-head.
• Phase 2a MASLD RCT (Sanyal/Nature Medicine 2024, n=98; PMID 38858523 / PMC11271400) — relative liver-fat reduction of −81.7% (8 mg) and −86.0% (12 mg) vs −4.6% placebo at 48 weeks; 89% (8 mg) and 93% (12 mg) reached normal liver fat (<5%). No hepatotoxicity signals.
• Bayesian network meta-analysis (Sinha & Ghosal 2025, 19 RCTs, n=29,506) [PMID 40685589]: retatrutide had the highest odds of ≥15% weight loss in class (OR 54.6 vs placebo), ahead of dual agonists (OR 16.4) and GLP-1 RAs (OR 9.0).
• Network meta-analysis (Xie 2024, 27 RCTs) [PMID 39305981] — retatrutide 12 mg (−22.1% body weight, −17.0 cm waist) and 8 mg (−20.7%) ranked first and second of all agents reviewed; tirzepatide 15 mg third. No agent significantly raised serious adverse events or hypoglycemia.
• Systematic review (Moiz/Annals 2025, 26 RCTs) [PMID 39761578] — retatrutide 12 mg produced up to 22.1% weight loss at 48 weeks, the highest of any agent, exceeding tirzepatide (17.8%) and semaglutide (13.9%).
• Meta-analysis (Abouelmagd 2025, 3 RCTs, n=878) [PMID 40291085] — significant reductions in weight (−14.33%), BMI, waist, fasting glucose (−23.51 mg/dL), HbA1c (−0.91%), and blood pressure; no significant difference in overall adverse-event rate vs placebo.

The clinician-reported longevity markers (Williams’s masterclass, from the 12 mg trial data, against the underlying Lilly publications): ~82% liver-fat reduction, 40% triglyceride reduction, 24% apoB reduction, 22% LDL reduction, ~10-point systolic BP drop, 72% of pre-diabetics returning to normal glucose, and fasting insulin cut by half or more at higher doses. The apoB number is the standout for the longevity audience — apoB is the gold-standard atherosclerosis-risk marker.

Animal data (first-class evidence for where this molecule’s mechanism is mapped):

• GIPR:GCGR co-agonism restored normal weight in obese rodents even with GLP-1 signaling absent — direct proof that GLP-1 alone doesn’t account for the result; the other two arms carry real independent weight. (Mechanism study; verify exact —.)
• Retatrutide improved steatohepatitis in a diet-induced mouse model [PMID 41056349] — reduced body weight, ALT, hepatic triglycerides/cholesterol, and inflammatory markers over a 2-week intervention.

Where experts and studies disagree: shown honestly: Williams reads the dose-response curve as continuing to climb (12 mg/68 wk = 28.7%, which he calls the largest mean weight loss in any obesity trial). One practitioner reads it as plateauing around 4–8 mg, citing roughly 17.5% at 4 mg and ~18% at 8 mg — “a 5% difference for double the dose.” Both agree on the practical takeaway: don’t chase the top of the curve. The honest reconciliation is that the marginal gain from 8→12 mg is small (the NEJM data show 22.8% → 24.2%) and the side-effect cost is large.

What’s still open: Phase 3 TRIUMPH has now read out topline-positive (TRIUMPH-1 and TRIUMPH-4), but the full peer-reviewed publications are not yet out — the headline Phase 3 percentages above are company-reported and tagged for verification; TRIUMPH-2 (T2D) and TRIUMPH-3 (CVD) are still pending. Still no liver-biopsy fibrosis data; durability past ~104 weeks unknown; trial populations skew white, US, non-diabetic. And the body-comp asterisk that matters most: roughly a quarter of weight lost can be lean mass if you don’t train and eat protein — which is exactly why the protocol below is non-negotiable on those two points.

Real-world protocol

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Reconstitution (objective math). A 10 mg vial reconstituted with 2 mL bacteriostatic water gives 5 mg/mL. On a U-100 insulin syringe (100 units = 1 mL), that’s 0.5 mg per 10 units:

• 0.5 mg = 10 units · 1 mg = 20 units · 1.5 mg = 30 units · 2 mg = 40 units
• Inject the water slowly down the side of the vial, swirl gently (never shake — shaking denatures peptide), store reconstituted in the fridge in the dark.

Two user types (Williams’s framework, the cleanest split in this space):

• Weight-loss user — BMI 27+, goal 15–30% body-weight loss. Higher doses, full titration, longer time on.
• Longevity / metabolic-optimization user — normal BMI, goal is moving the markers (insulin sensitivity, liver fat, lipids, apoB, BP, inflammation). Low dose, often microdose; weight loss is modest but the metabolic gains are well preserved.

Standard titration (weight-loss user, Williams):

Weeks	Dose	Note
1–4	2 mg/wk	Never start higher
5–8	4 mg/wk	If needed
9–12	6 mg/wk	If needed
13–17	8 mg/wk	Sweet-spot ceiling for most users
(rare)	12 mg/wk	Severe obesity / non-response only

Where experts differ on the start: one practitioner starts lower and gentler — 0.5 mg/wk for weeks 1–2, double to 1 mg, then step up ~0.5 mg every two weeks — which suits a lean or side-effect-sensitive user. Williams’s 2 mg start matches the obesity-trial starting point. Both are valid; pick by user profile. Lean longevity start: 1 mg/wk, hold 4 weeks, increase to 2 mg only if needed — most lean users find their working dose at 2–4 mg.

Frequency. Once weekly matches the trials (4:1 peak-to-trough, some end-of-week hunger). Splitting to twice weekly cuts the peak ~28% and three-times-weekly ~38%, smoothing appetite and lowering injection-day nausea — PK-modeled, not trial-validated, but widely reported as a smoother ride. Morning vs night is pharmacokinetically a wash (a 6-day half-life means <15% swing across 24 hours) — pick the timing that lands the 4–24-hour side-effect window where it bothers you least.

Cheat-sheet convention (a commonly used practitioner protocol): 10 mg vial in 2 mL, 0.5–1 mg dosed AM, 3–4×/week — note this is a lower weekly exposure than the once-weekly trial protocol; it reflects a split-dosing, lower-dose approach.

Tirzepatide → retatrutide crossover (don’t jump same-dose): walk Tirz down 15 → 10 → 5 → 2 mg, cross to 2 mg Reta, re-titrate up. 4–8 weeks. Skipping the walk-down is the #1 cause of a GI catastrophe on the switch.

Cycling. Three honest models: chronic (indefinite, for those who won’t change lifestyle), cycled/“blast-and-cruise” (6–12 month active windows + maintenance taper), and pulsed (12–24 week cycles even at goal, for liver-fat/lipid benefit). Roughly 76% of weight loss is regained within ~23 weeks of stopping cold, so plan a taper (drop every 4 weeks, e.g., 8→6→4→2→off) and a maintenance dose rather than a hard stop.

⚠️ Crash-dieting trap: sub-800 cal/day on Reta is silent self-sabotage. Reta’s appetite suppression is powerful enough that many users drift below 800 cal/day without realizing it — they’re not hungry, so they don’t eat, and they assume that’s the medication working. It is the medication working, but working too well and not being managed. Three consequences compound:

1. Gallstones. Rapid weight loss + slowed gallbladder motility → stone formation. Sudden right-upper-quadrant pain after a fatty meal warrants evaluation.
2. Vitamin / mineral deficiencies. Not eating enough food = inadequate micronutrient intake. Hair loss, brittle nails, fatigue are warning signs, not cosmetic complaints.
3. Accelerated muscle loss. Below ~800 cal/day, even with protein + training, the lean-mass cost of weight loss accelerates beyond what the GLP-1 muscle-preservation signal can offset. Replacing lost muscle takes meaningfully longer than preserving it would have — a once-lost muscle deficit becomes a long-term recovery project.

Practical guards: track calories at least intermittently when starting Reta (you can’t manage what you don’t measure); never drift below 1,200 cal/day for women, 1,500 for men, even when not hungry; protein is non-negotiable (see the four-non-negotiables above); supplement a quality multivitamin during the active titration window.

The weekly therapeutic-fast framework (a dieting-strategy alternative to chronic daily restriction). As an alternative to chronic daily caloric restriction (which downregulates RMR via metabolic adaptation, badly exacerbated by GLP-1s), one widely-used clinic protocol contains the weekly deficit in a concentrated window:

• One 36–48 hour therapeutic fast per week. This contains the weekly caloric deficit in a single concentrated window.
• Eat at total daily energy expenditure (TEE ≈ 2,000 kcal for most users) on the other 5 days. No deficit on eating days — just maintenance-level intake.

Same weekly caloric deficit, dramatically different metabolic outcome. The therapeutic fast triggers the autophagy / mTOR-suppression / insulin sensitization benefits of extended fasting (established physiology), while the 5 days at TEE prevent the chronic-restriction RMR downregulation that drives plateau on conventional calorie-deficit dieting. The weekly-fast pattern is a dieting-strategy framework, not a drug-cycling model — it stacks with the existing three cycling models above. It suits the existing low-and-slow + foundation-first framing: a Reta user who builds protein + resistance training + creatine + a weekly therapeutic fast + a therapeutic ≤4 mg/week Reta dose often achieves better fat:lean ratio than a user who runs a higher Reta dose on chronic daily caloric restriction.

🚨 Hard rule: never stack with another GLP-1 receptor agonist. Do NOT combine Retatrutide with Semaglutide (Ozempic / Wegovy), Tirzepatide (Mounjaro / Zepbound), Liraglutide, or any other GLP-1 receptor agonist. All of these molecules bind the same GLP-1 receptor (and Retatrutide additionally adds GIP and glucagon arms). Stacking them double-binds the receptor and compounds the entire side-effect tail — GI severity, hypoglycemia risk, gallstone and pancreatic stress, dehydration, electrolyte loss, and heart-rate effects all stack — without a corresponding compounding of the weight-loss benefit. Pick one drug in this class and titrate it slowly. The protocol builder on this site enforces this rule and will warn you if you try to combine them. This applies across the whole class: semaglutide ⨯ tirzepatide, semaglutide ⨯ retatrutide, tirzepatide ⨯ retatrutide — none of these combinations are safe or productive.

Practitioner counter-view: a supervised low-dose Tirz + low-dose Reta BLEND. Some practitioners distinguish stacking (cranking each at higher doses) from blending (lowest-effective-dose of each). The framing: Tirz delivers the strongest appetite suppression in the class, crushing food noise and making portion control effortless, but has no glucagon arm; Reta carries the glucagon arm that drives fat oxidation, energy expenditure, and a better fat-to-lean-mass loss ratio. Combining at sub-therapeutic monotherapy doses — a typical starting protocol being roughly Reta 0.5–1 mg + Tirz ≤2.5 mg — gives access to both pathways without the side-effect burden of either at full strength. Target population in those clinics: fatty liver disease, significant metabolic dysfunction, or plateau on Tirz monotherapy. The hard caveats from clinicians who use this approach: it requires medical supervision, blood-work monitoring, and careful titration — and is explicitly not a self-administered protocol. The pharmacological reasoning is sound (overlapping GLP-1 + GIP receptors at lower combined dose can give similar activation with reduced side-effect tail).

OHM’s resolved position on the Tirz + Reta blend (2026-06-18):

• The OHM protocol builder continues to enforce the Hard Rule above — it rejects any combination of GLP-1 RAs. This is appropriate because the builder is a tool for self-directed users who don’t have a prescriber-relationship layer monitoring labs and titration. Combining GLP-1 RAs without that layer is the failure mode the Hard Rule prevents.
• Pep (the OHM chatbot) reports the landscape honestly, not dogmatically. When users ask about combining GLP-1 RAs, Pep’s correct answer is: the practice is generally not advised; some qualified clinicians guide patients through a careful low-dose blend under medical supervision with lab monitoring; and this is a conversation to have with a prescribing physician familiar with the approach, not something to attempt on your own. Pep is a reporter of how these peptides work and how qualified clinicians actually use them — not a dogma-pumper.See for the full digest of Jones’s framework + the editorial-decision context.

Stacking. Multiple practitioners in the OHM source library endorse pairing Reta with a GH-support peptide (Tesamorelin / CJC-1295 / Ipamorelin) to preserve lean mass, and BPC-157/TB-500 (Wolverine (BPC-157 + TB-500)) for joints and recovery. One widely-cited longevity stack pairs Retatrutide (metabolic lever) + GHK-Cu (gene-expression lever) + MOTS-c (mitochondrial lever), with the consistent clinical observation that low-and-slow Reta dosing beats high-dose. For men running Reta as part of a body-composition protocol, optimizing hormones (TRT, thyroid, sleep) first is a common practitioner-camp prerequisite — though that’s the recomp framing; a lean longevity user running low-dose Reta with adequate protein and training does not need TRT first.

⏰ The GH-peptide timing rule on Retatrutide (the part most stack-runners miss). The standard “wait 2 hours after eating before pinning your GH peptide” rule doesn’t hold on a GLP-1 receptor agonist — and Reta’s GLP-1 arm activates the same gastric-emptying brake. GLP-1 agonism measurably slows gastric emptying: the time for half a meal to clear the stomach stretches from a normal ~2 hours to approximately 3 hours, with measurably more food still in the stomach at the 2-hour mark and the gap widening at 3 hours, not narrowing for the specific ~25% magnitude at the 2-hour mark]. The effect is large enough that the ASA issued formal pre-operative guidance in June 2023 recognizing retained gastric content even after a standard 8-hour preop fast in patients on GLP-1 RAs. So when you eat dinner at 7 PM and pin CJC/Ipamorelin or Tesamorelin at 9 PM thinking you’re fasted — you’re not. Insulin is still elevated, and insulin binds directly to pituitary somatotrophs and suppresses the GH pulse you’re injecting for [established endocrinology]. You’re paying for a pulse you’re not getting.

The fix: move the GH-axis peptides to first thing in the morning (the only window you’re reliably fasted on a GLP-1 RA, because overnight fast has cleared the stomach). Eat your first meal 30-60 minutes after the GH-peptide injection — that gives the GH pulse time to fire AND lets the post-meal insulin anchor the IGF-1 conversion in the liver. The “pin before bed” convention that works fine for non-GLP-1 users fails on Reta; the morning protocol is the stack-compatible version. The rule applies across the GLP-1 class (Reta, Semaglutide, Tirzepatide).

Cross-compound thinking: this is the same operational pattern as the SS-31 → MOTS-c sequencing rule — when you stack two peptides, the way they interact changes the timing rules. Whole-stack thinking, not single-peptide thinking, is OHM’s house position on protocol design.

The four non-negotiables: protein, resistance training, lowering fasting insulin, and Creatine — the foundational muscle + brain + metabolic adjunct (especially on a GLP-1). A 100 kg person losing 25% body weight loses ~25 kg total, of which 5–7 kg will be lean mass: normal, but largely avoidable. Target ~1 g protein per pound of lean body mass (or Froese’s absolute targets: men 150–200 g/day, women 100–130 g/day) plus 2–3 resistance sessions/week. Without these, you get a smaller, weaker version of yourself instead of a leaner, stronger one. Jones (2026) adds a foundational prerequisite: intermittent fasting (or any structured fasting protocol) to lower baseline insulin before adding Reta. The mechanism + the failure mode: Reta’s glucagon arm drives hepatic glucose output + lipolysis up — desirable in a metabolically fit, training, time-restricted-eating user, but if insulin resistance is still high AND the user isn’t training, that same glucagon activation can backfire — the freed glucose can’t be efficiently cleared and the elevated free fatty acids can compound metabolic dysfunction rather than resolve it. The fix isn’t to remove Reta; it’s to build the foundation that lets the glucagon arm do useful work. Jones’s clinical observation: patients who run intermittent fasting + resistance training + adequate protein as the foundation often see meaningful results at ≤4 mg/week of Reta — meaningfully lower than the ~10 mg/week or higher used in TRIUMPH and the other trials. This is the empirical anchor under the “low and slow beats high-dose” mantra: the trial doses are the ceiling for people who haven’t built the foundation; for people who have, the working dose is roughly half (or less) of the trial target.

The fourth non-negotiable — Creatine — the foundational muscle + brain + metabolic adjunct (especially on a GLP-1) for muscle preservation + cognitive support + adipose thermogenesis. Creatine is not a peptide and not a gym supplement — it’s a cellular energy compound (ATP-regeneration substrate via the phosphocreatine system) that becomes more relevant, not less, as you age. For the Reta customer specifically, three mechanisms compound on top of the existing fat-loss signal: (1) ATP availability driving basal metabolic rate — energized cells oxidize fat; tired cells defend energy stores; (2) the futile creatine cycle in beige and brown adipose tissue (Kazak et al. 2015, Cell 163:643-655; PMC4656041), which drives mitochondria in active fat cells to consume more energy as heat independent of training; (3) GLUT4 upregulation in skeletal muscle during rehabilitation from disuse atrophy, improving glucose handling. Dosing: 5 g/day every day, with a meal containing carbs + protein, with adequate hydration. Critical absorption rule: the standard “morning, fasted, in plain water” protocol is approximately the worst-possible conditions — SLC6A8 (the creatine transporter) is sodium-dependent and insulin-driven, so taking it with a real meal that generates an insulin response augments retention substantially (Green et al. 1996 Acta Physiol Scand, PMID 8899067 — verified). This same insulin-state-dependent uptake mechanism is why “morning fasted in water” also undermines GH-peptide protocols on Reta (see § Stacking → the GH-peptide timing rule on Retatrutide above). One foundational nutrition pattern (food + hydration + dosed timing) fixes both. See Creatine — the foundational muscle + brain + metabolic adjunct (especially on a GLP-1) for the full mechanism, protocol, absorption science, and stacking rules.

Carbohydrate intake on Retatrutide — the glucagon-arm-specific mechanism case.

The mechanism case for adequate carbohydrate intake on Reta is sound and is specific to the glucagon arm that Reta carries and the other GLP-1 RAs do not. This is the central nuance, because it determines what cross-compound evidence actually transfers to this question:

• Semaglutide is a single GLP-1 agonist.
• Tirzepatide is a dual GLP-1 + GIP agonist with no glucagon receptor activity (verified 2026-06-18 against the Tirz pharmacology literature — Coskun 2020 + multiple JCI/PNAS papers confirm Tirz is a dual GLP-1 + GIP receptor agonist).
• Retatrutide is the only currently-prescribed incretin compound with glucagon receptor agonism in the mix (triple GLP-1 + GIP + glucagon).

The keto-on-Reta question therefore has different biology than the keto-on-Sema or keto-on-Tirz questions, and evidence from the other compounds cannot be cross-applied to this one.

The mechanism, glucagon-specific:

• Reta’s glucagon agonism drives hepatic gluconeogenesis — the liver pulls substrate to maintain blood glucose. When carbs are adequate, the substrate comes from glycogen + glycerol; when carbs are restricted (keto / very-low-carb), glycogen depletes and the liver under sustained glucagon signaling pulls from muscle protein via amino-acid gluconeogenesis. Net result: glucagon-driven sarcopenia from your own peptide protocol.
• Sema and Tirz do not carry this risk by the same mechanism because neither one activates the glucagon receptor. Without sustained glucagon signaling, the specific muscle-protein-to-glucose pathway Reta drives under low-carb conditions simply doesn’t fire. The keto-on-Sema and keto-on-Tirz questions are real and worth evaluating on their own merits — but they’re different metabolic questions with different mechanisms.
• Supporting Reta-specific biochemistry: GLP-1 sensitizes β-cells to glucose (low-carb → low glucose spikes → first-phase insulin release underutilized); GIP amplifies insulin’s anabolic effect on carbs (no carbs → no substrate); glycolysis via pyruvate yields more ATP per molecule than ketones do via β-hydroxybutyrate, which matters because Reta increases mitochondrial ATP demand via uncoupling proteins.

The general practitioner position — endorsed broadly across the metabolic-medicine practitioner camp — is 40–55% of total calories from carbohydrate on Reta, with the carbs coming from rice / potatoes / oats / sourdough / fruit (the easy-digesting list above), not refined sugar. The case is biochemistry-based and the direction is biologically valid.

One widely-cited number doesn’t hold up to verification. A specific claim circulating in the practitioner camp — that a 2020 Obesity journal study showed 8% vs 22% weight loss with low-carb vs balanced-carb Retatrutide — cannot be accurate, because Retatrutide didn’t enter human trials until 2022 (Jastreboff Phase 2 in NEJM 2023 was the first significant publication). The specific 8% vs 22% number isn’t verifiable in primary form. The mechanism direction stands; the specific number doesn’t, and OHM doesn’t propagate it as fact.

Cross-compound evidence transfer is the trap to avoid. Recent 2025 evidence (PMC11990520) shows that tirzepatide + low-energy ketogenic therapy outperformed Tirz + low-calorie diet on fat-free mass preservation. This study is NOT counter-evidence to the Reta + keto thesis — Tirz is a dual agonist with no glucagon receptor activity, so the muscle-catabolism mechanism that drives the Reta caution (sustained glucagon signaling → hepatic gluconeogenesis → muscle protein when low-carb) is not present in a Tirz protocol. The PMC11990520 finding is informative for users running Tirz; it does not transfer to Reta. The keto-on-Reta question has to be evaluated on Reta’s own glucagon-driven biology, and no published RCT directly compares keto vs moderate-carb on Reta to date. Until such a trial exists, the mechanism case for moderate carbs on Reta is the best evidence available, and it points clearly.

OHM’s three-part frame for users considering low-carb / keto on Reta (per the peptides/ § “Pep as reporter, not dogma-pumper” doctrine):

1. General position: Reta’s glucagon agonism creates a specific mechanism by which sustained low-carb states drive gluconeogenesis from muscle protein. The metabolic-medicine practitioner consensus is to keep carbohydrate intake in the 40–55%-of-calories range when running Reta. The mechanism for this caution is established endocrinology and is genuinely Reta-specific — it does not generalize to Sema or Tirz, which lack the glucagon arm.
2. Practitioner landscape: the mechanism-based case for moderate carbs on Reta is broadly endorsed across the metabolic-medicine practitioner camp. No published RCT directly tests keto vs moderate-carb on Reta yet. Recent keto-on-Tirz evidence (PMC11990520) is favorable for that compound, but Tirz lacks the glucagon arm — so that result is informative for Tirz protocols, not Reta.
3. Route to user’s clinician: if you’re running keto or low-carb on Reta — particularly given the glucagon arm — monitor labs (electrolytes, kidney function, ketone levels, lean mass via DXA if available), maintain protein at ≥1.6 g/kg (or the ~1 g/lb-of-goal-weight target above), and work with a prescribing clinician familiar with the Reta-specific glucagon biology and ketogenic protocols.

Pep’s editorial behavior on this question: Pep surfaces the glucagon-arm-specific mechanism + the moderate-carb practitioner consensus + the distinction that keto-on-Tirz evidence does NOT transfer to Reta + the route to the user’s clinician. Pep does not cite the PMC11990520 Tirz study as evidence for or against keto-on-Reta — they’re different molecules with different mechanisms relevant to this question.

Side effects & management

The mechanism explains the side effects, and the mechanism gives you the fixes. (Froese’s six-category framework + Williams’s mitigations.)

GI cluster — nausea (~27%), diarrhea (~23%), vomiting (~18%). Retatrutide “puts a brake pedal on your digestive highway” by slowing gastric emptying. Fix: slow titration (every 4 weeks minimum, 6–8 weeks better — slow titration reportedly cuts GI side effects ~79% vs rapid), smaller meals, limit liquids during meals, and aggressive hydration (GLP-1s blunt thirst, so people dehydrate). Sulfur burps are hydrogen-sulfide gas from food fermenting in the slowed gut — unpleasant, not dangerous; digestive enzymes help.

Two GI-trap food/drink patterns Reta-specific:

• Greasy / processed / seed-oil / fried meals. Reta’s gastric-emptying delay is more aggressive than Sema or Tirz, so a fat-heavy treat meal that you got away with on the GLP-1 monoagonists can wreck a Reta titration. During the early titration phase especially, decrease total fat and shift to smaller, more frequent meals. The body can adapt to higher fat intake over time; just don’t push it before adaptation.
• Large portions + carbonated drinks. The seemingly-healthy salad-plus-sparkling-water combination is a trap on Reta — large volume into a slowed stomach plus carbonation gas that can’t release leads to severe bloating, abdominal pressure, and the sense that the meal is just sitting there refusing to move. Drop the carbonation; eat smaller meals during adaptation.

The positive “eat-this” Reta titration food checklist — the complementary affirmative framing to the “avoid this” list above:

Pick	Why it works on Reta
Lean proteins — chicken breast, white fish, whey protein, lean beef	Low fat content → easier on slowed digestion; preserves muscle on caloric deficit
Easy-digesting carbs — rice, potatoes, oats, sourdough, rice cakes, fruit	Digest smoothly with slowed gastric emptying; minimal bloating; reliable energy without crashes
COOKED vegetables, not raw	Cooking pre-breaks down the fiber matrix (hemicellulose + cellulose softening) → far gentler on the slowed-emptying gut than raw “fiber bombs” (raw cruciferous, raw green beans, raw legumes). Raw vegetables on Reta = gas + bloating + constipation. The “eat your greens” advice changes on a slowed-gut protocol — cook them, don’t skip them.
Water + electrolytes — sodium (Celtic salt is fine), magnesium, an electrolyte mix from the pharmacy	Reta blunts thirst signal AND reduces food (= reduces water-from-food) intake → automatic dehydration deficit that compounds the GI side-effect tail + the four-way kidney assault risk. Plain water alone underperforms — pair with electrolytes.

Three tactical eating rules for the Reta user — established nutritional physiology [established]:

1. Eat slowly. The fullness signal takes 15–20 minutes to register at the hypothalamus (the ghrelin / leptin / PYY cascade isn’t instant). On a normal stomach, “smashing a meal in 5 minutes” just means you finish too soon and feel mildly uncomfortable. On Reta’s slowed-emptying stomach, the same behavior dumps the entire meal into a gut that can’t process it, and you feel severely overfull + gas + bloating within 10–15 minutes after eating. The same satiety mechanism that’s supposed to be helping you eat less can’t help if you outrun it.
2. Spread your fats across meals — don’t load 40+ grams into one sitting. Fats are essential (hormones, fat-soluble vitamins, satiety) — the “avoid high-fat meals” rule above is NOT “eat zero fat.” It’s “don’t concentrate the day’s fat allotment in one meal.” Distribute across 3–4 meals and you get the nutrition without the slowed-stomach Reta-specific overload.
3. Pair sugar with protein when you DO eat sugar. Reta’s glucose-control mechanism is real but it doesn’t eliminate spikes from high-glycemic foods (pastries, soft drinks, chocolates) — you can still get the spike + crash + “jelly legs” cycle. Mitigation: pair the sugary food with protein (e.g. dessert + Greek yogurt; soft drink + protein bar). Protein co-ingestion slows glucose absorption + blunts the postprandial spike + reduces the crash. Useful for the inevitable “I had dessert” moment.

⚠️ The four-way kidney assault: NSAIDs + ACE inhibitor / ARB + diuretic + GLP-1 This is the highest-leverage net-new safety item in the OHM KB for GLP-1 users — easy to miss because each medication individually is manageable, but the four-drug combination is a real acute kidney injury risk:

Medication	Renal mechanism
NSAID (ibuprofen, naproxen, Motrin, etc.)	↓ renal prostaglandin synthesis → constricts afferent arteriole → ↓ renal blood flow
ACE inhibitor / ARB (lisinopril, losartan, etc.)	Dilates efferent arteriole → ↓ glomerular filtration pressure
Diuretic (HCTZ, furosemide, spironolactone, etc.)	↓ plasma volume → ↓ renal perfusion
GLP-1 RA (Reta especially)	GI side effects → dehydration → ↓ renal perfusion

Net effect: kidney blood flow squeezed from every direction at once. With 2 of these, tolerable + worth the medication benefit; with 3 or 4 = real acute kidney injury risk. The mechanism is hemodynamic (renal blood flow starvation), NOT direct nephrotoxicity — meaning there’s no pain, no warning sign, just a creatinine spike when labs come back. The honest clinical read from practitioners managing GLP-1 patients on multi-drug regimens: long-term safety data on this combination is still emerging, and the right move is to err toward caution rather than risk discovering the issue retroactively in lab work.

Practical rule for the OHM customer: never start a GLP-1 protocol without a medication review for NSAID + antihypertensive + diuretic combinations. If on any of these, work with the prescriber on hydration protocol + possibly transitioning NSAIDs to acetaminophen / topical NSAIDs / different-mechanism analgesic during the GLP-1 titration window. Don’t stop any prescribed medication on your own — work with the prescriber.

Fatigue + sleep + cramps: one cascade. This is Froese’s cleanest insight: the insulin drop signals the kidneys to dump sodium and water, so low blood sugar + low sodium + low water = exhaustion, and the same loop runs overnight. It’s the drug working, not failing. Fix: electrolytes — sodium + water as the primary lever, plus magnesium glycinate for the nervous-system/cardiac side. Magnesium oxide at night helps constipation (avoid daytime — it pulls water into the gut).

Elevated resting heart rate — the most distinctive Reta effect, ~5–10 BPM at higher doses (vs 2–4 with sema/tirz). ✅ VERIFIED 2026-06-18 against TRIUMPH trial data: at 12 mg, peak ~6.7 BPM at week 24, declining toward baseline by weeks 36-48; at 4 mg (low-dose), ~2-4 BPM (comparable to Tirz). Individual variability is real — some patients exceed 10 BPM. The mechanism is specific: glucagon receptors sit on the heart’s natural pacemaker, the sinoatrial (SA) node, and Reta stimulates it directly. A useful way to think about the scale: a +7–10 BPM rise at the highest dose adds up to roughly fourteen thousand extra heartbeats per day — the cardiac equivalent of light continuous low-grade exertion running in the background. Manageable for a healthy heart, but unproven long-term for anyone with underlying cardiac disease. Fix: taurine 5–10 g/day (widely endorsed in the practitioner camp as a standing adjunct for any Reta user) + magnesium glycinate + hydration. If resting HR keeps spiking, monitor it and titrate the dose down rather than pushing through — the cardiac strain accumulates silently. Persistent resting HR over 100, palpitations, irregular rhythm, or chest pain → pause and get evaluated.

⚠️ Stimulant stacking — Reta-specific, not class-wide. Because Reta carries this baseline HR elevation that Sema/Tirz don’t, stimulant stacking has a different risk profile on Reta than on the other GLP-1 RAs. Audit total stimulant intake when starting Reta:

• Caffeine (coffee, tea, soda) — track total mg/day, not just cups
• Pre-workout supplements (often 150-400 mg caffeine + other stimulants)
• Energy drinks (often 150-300 mg caffeine + taurine + B-vitamins + sugar)
• Fat burners / “thermogenic” supplements (synephrine, yohimbine, etc.)
• ADHD medications (Adderall, Vyvanse, Concerta, Ritalin, Strattera) — stimulant class, talk to prescriber, don’t stop on your own

A representative clinic case from the practitioner literature: a Reta patient who continued 2 energy drinks/day plus a prescribed ADHD stimulant ran a resting heart rate well above the acceptable range — the clinical fix was pulling the stimulant load before continuing the peptide. Practical rule: when starting Reta, cut total daily caffeine to ≤200-300 mg AND skip pre-workout / energy drinks for at least the first 12-16 weeks while the HR effect is peaking. Once you’re past the week 24 peak and the HR has stabilized, you can carefully reintroduce. If you’re on ADHD stimulants, talk to your prescriber before adding Reta — dose adjustment may be needed.

Pancreatitis + alcohol — pancreatitis is a low-rate class concern across GLP-1s; severe upper-abdominal pain radiating to the back means stop and get seen. Reta’s glucagon arm adds liver stress on top of the class concern, and at least one mid-stage Reta trial reported a case of acute pancreatitis. Alcohol multiplies the risk through three independent mechanisms: GI stress on an already-stressed system; dehydration on top of GLP-1-driven dehydration; direct pancreatitis + gallbladder risk on its own. The trap: GLP-1 RAs reduce the desire to drink in many users, who then assume alcohol is no longer a problem. The opposite is true — when you DO drink on Reta, the risks stack. The honest customer-facing read: moderate, occasional, hydrated alcohol consumption is defensible. Binge episodes on Retatrutide carry meaningfully elevated risk of acute pancreatitis, gallbladder disease, and GI distress — they’re a category where the prudent answer is: don’t.

Birth control / hormonal contraception interactions Two-part problem most users + many prescribers don’t flag:

1. Reduced oral contraceptive absorption. Reta’s gastric-emptying delay slows oral pill absorption + vomiting (common Reta side effect) can interfere with pill uptake entirely. Your birth control pill may not be reaching effective serum levels — meaning contraceptive failure even when taken on the standard schedule.
2. Restored fertility on a GLP-1 RA. GLP-1 receptor agonists restore ovulation in women with PCOS / metabolic-driven infertility via weight loss + improved insulin sensitivity + hormonal rebalancing. Patients who were told they likely couldn’t conceive are getting pregnant unexpectedly on these protocols. This is a real, documented signal across the GLP-1 class.

Practical recommendation: switch to a non-oral backup contraception method for the duration of the GLP-1 protocol — an IUD (the copper IUD is widely preferred in the practitioner camp as less reactive than hormonal IUDs), an implant, or another non-oral method that doesn’t depend on stomach absorption. Don’t stop oral contraception unilaterally — coordinate with the prescriber. This applies across the GLP-1 class (Semaglutide, Tirzepatide, Reta) — not Reta-specific.

Anesthesia / surgery — disclose your GLP-1 RA to every clinician. Reta’s gastric-emptying delay means food can still be in the stomach even after the standard 8-hour preop fast → aspiration risk under sedation. The American Society of Anesthesiologists issued formal consensus guidance in June 2023 (verified earlier this session) recommending GLP-1 RA users hold the drug for ≥1 half-life before elective surgery + emphasizing the residual gastric content risk. Tell the anesthesiologist, surgeon, AND nurse — don’t assume they know. Applies to colonoscopy, dental sedation, any procedure with sedation, not just major surgery.

Allodynia / skin sensitivity — 7% at lower doses, ~21% (1 in 5) at 12 mg in obesity trials, only ~2% at 12 mg in diabetics. Feels like sunburn without sun; glucagon receptors on sensory neurons temporarily lower the pain threshold. Fix: dial the dose back a few weeks then re-titrate; topical magnesium spray + hydration for acute relief.

Anhedonia / emotional flattening — a quieter, under-discussed effect at higher doses: in addition to silencing the food noise the drug is engineered to silence, some users report a broader flattening of motivation and everyday pleasures alongside it. Retatrutide modulates dopamine in the brain’s reward center (the nucleus accumbens), and at higher doses some users describe hobbies, coffee, and everyday pleasures shading into grayscale (mechanistically plausible but not trial-quantified). Fix: if mood or motivation noticeably dulls, dial the dose down and find the lowest effective dose — it’s a signal, not something to push through.

Muscle loss — covered above; protein + resistance training is the only real prevention. A useful clinical threshold from the practitioner literature: losing faster than ~2% of body weight per month tips the body into an emergency catabolic state, and replacing lost muscle is far harder than not losing it. Target 1.2–1.5 g/kg protein as the conservative clinical floor; physique-optimization targets in the broader practitioner literature run higher (~1 g per pound of goal weight), with leucine-rich sources.

Which muscles actually lose? The honest answer that addresses the “is this drug eating my heart or my gut?” fear (verified 2026-06-16). This is the most common GLP-1 concern, and the verified answer is reassuring:

• Skeletal muscle: REAL loss, manageable. SURMOUNT-1 DXA substudy (Look 2025, n=160, DOI 10.1111/dom.16275): at 72 weeks on tirzepatide, body weight dropped 21.3%, fat mass 33.9%, lean mass 10.9%: so ~75% of the weight loss came from fat, ~25% from lean mass. A 2025 Pharmacological Research class-level review (S1043661825003524) puts the lean-mass share at 20–30% of total weight loss across the GLP-1 class — consistent with placebo and typical caloric-restriction diet outcomes. The same review notes preclinical models show GLP-1 RAs protect skeletal muscle (intramuscular lipid down, mitochondrial health up) while human studies are mixed (some show excess lean-mass loss; some show sarcopenia protection). Bottom line: skeletal muscle loss is real but largely preventable with resistance training + adequate protein.

• Cardiac muscle: an honest nuance, not a hidden danger. Two domains of evidence:

  • In obesity-related HFpEF (heart-failure-with-preserved-ejection-fraction), LV mass reduction is BENEFICIAL remodeling, not harm. The SUMMIT trial CMR substudy (JACC 2024, PMID 39566869) found tirzepatide reduced LV mass by 11 g and paracardiac adipose tissue by 45 mL vs placebo, paralleling weight loss — unloading a hypertrophied heart is the goal in this population. STEP-HFpEF (semaglutide in HFpEF) showed favorable left-atrial remodeling, with HF events and symptoms improved. The HFpEF outcomes are net-positive.
  • In healthy users, a direct cardiomyocyte effect is observed in mice but the structural integrity and function are preserved. The University of Alberta semaglutide mouse study (JACC: Basic to Translational Science Oct 2024, PMID 39822607) found cardiomyocyte size + cardiac mass reductions in both lean and obese mice with no changes in wall thickness, septum thickness, fibrosis genes, or atrophy genes — and no functional impairment at rest. The honest gap: long-term cardiac-muscle data in healthy chronic GLP-1 users hasn’t been published yet. What we have: reassuring HFpEF data + reassuring short-term mouse data + no signal of human cardiac dysfunction at therapeutic doses. What we don’t have: 10-year human cardiac-muscle follow-up.

• Smooth muscle (esophagus, gut, vital organs): no published human evidence of dangerous loss at therapeutic doses with reasonable nutrition. The mechanism story is the hierarchical-preservation order under caloric deficit: fat goes first → skeletal muscle next (the protein reserve) → vital organ muscle and smooth muscle last (protected until extreme starvation). GLP-1 drugs induce a moderate, controlled caloric deficit — not the prolonged severe malnutrition that would deplete vital-organ structural protein. This hierarchical-preservation pattern is well-established physiology, observed in caloric-restriction studies and historical famine data alike.

Operational takeaway for the worried-friend audience: at therapeutic doses with reasonable nutrition, GLP-1 drugs primarily reduce skeletal muscle, which you can actively protect with resistance training + protein. Cardiac muscle effects exist but are net-beneficial in HFpEF and preserved-function in the available healthy-user data. Smooth muscle: no evidence of dangerous loss. Full verification record + study links in.

Rare but serious: know these. Gallstones (any rapid weight loss raises risk; sudden right-upper-quadrant pain after a fatty meal → evaluate) and pancreatitis (theoretical class risk, low actual rate; severe upper abdominal pain radiating to the back → go to a doctor). These are the two “don’t push through” red flags.

Oral-medication absorption. Like the rest of the GLP-1 class, retatrutide slows gastric emptying and can change how quickly oral drugs are absorbed. Usually minor; space or flag time-sensitive oral medications and discuss narrow-margin drugs with your prescriber.

The autoimmune patient stalled on retatrutide — the inflammation-driven plateau

A use case worth surfacing here, since the autoimmune population is a meaningful slice of the Reta user base. Autoimmune patients (Hashimoto’s, IBD, MS, RA, lupus, psoriasis, fibromyalgia) who plateau on a GLP-1 RA almost always have an inflammation-driven insulin-resistance ceiling that the GLP-1 alone can’t fully break. Mechanism: chronic elevated TNF-α, IL-6, and IL-1β activate intracellular kinases (JNK, IKKβ) that phosphorylate IRS-1 on serine residues, blocking the normal insulin-receptor cascade. Cells become insulin-resistant from the inside while the receptor at the surface still functions. Result: elevated insulin → fat-storage mode → Reta’s modest anti-inflammatory effect can’t fully overcome the load.

The intervention: layer in Low-Dose Naltrexone at 1.5 mg evening, titrating to 4.5 mg over 4–8 weeks. LDN modulates the immune system from a different angle than Reta (endorphin rebound + TLR4 antagonism on microglia → reduced inflammatory cytokine output + reduced neuroinflammation). No known pharmacokinetic interaction. The practitioner landscape strongly endorses LDN-as-adjunct for the autoimmune-on-GLP-1 plateau. Patients adding LDN often see weight loss resume within 4–8 weeks as inflammatory markers (CRP, ESR) drop. For persistent gut symptoms, add the BPC-157 + KPV gut-barrier layer (oral BPC 500 µg/day + KPV co-administered; both in KLOW). For severe / multi-condition autoimmune presentations, Thymosin Alpha-1 at weeks 8–12 adds T-cell-level immune retraining on top of LDN’s storm-calming effect.

LDN is not commercially manufactured at the 1.5–4.5 mg dose range — it’s compounded by a 503A pharmacy from the standard 50 mg naltrexone tablet, with a prescription from a functional-medicine physician, telemedicine clinic, or any prescriber familiar with LDN. See Low-Dose Naltrexone (LDN) — the immune-modulation bridge for autoimmune patients on GLP-1s for the full mechanism, dosing, safety profile (the critical contraindication: do not combine with any opioid medication), and access path.

Regulatory status

Investigational and not yet FDA-approved as of mid-2026; Phase 3 TRIUMPH trials are reading out, with Lilly reporting a successful TRIUMPH-4 readout and an NDA filing expected in the 2026–2027 window. Sold as a research-use-only compound. Not on the WADA-relevant approved-therapeutics list. The April-2023 GLP-1-class FDA shortage history is the backdrop for the compounded/research-chemical market it currently sits in.

The Alyve product

Alyve carries retatrutide in 10 mg ($104) and 20 mg ($164) vials (30 mg variant listed at $228, currently out of stock). Third-party COA from Freedom Diagnostics Testing (HPLC-UV purity + LC-MS identity confirmation): 99.01% on the 10 mg (lot RET750, net 10.47 mg) and 99.13% on the 20 mg (lot RET602, net 23.96 mg) — both identity-confirmed as retatrutide, net content beating label.

That matters more here than almost anywhere, because the gray market is rough: independent testing has found roughly 1 in 4 research peptides are underdosed, mislabeled, or contaminated — often with TFA salt left over from synthesis and no COA at all. A verified >99%-pure, identity-confirmed, US-handled product is the clean tier, and the COA is the proof.

Independent corroboration of the variability problem (2026-06-16). Fitness creator Ryan Humiston sent a research-grade Retatrutide vial labeled 60 mg for third-party analytical testing and the bottle came back at 108 mg actual content: 180% of label claim. The overdose direction is the same QC failure as the underdose direction (and arguably more dangerous for titration-discipline: a “0.5 mg” start dose calculated off that vial would actually be 0.9 mg, well into the GI-event range for many users). External validation of the same supply-chain thesis — verified-vendor + COA isn’t a marketing layer, it’s the difference between titration that works and titration that doesn’t. Cross-link to Tirzepatide for the compoundable-vs-not regulatory distinction (Tirz is compoundable via FDA-regulated 503A/503B pharmacies under shortage status; Reta is not).

Use code OHM-15 for 15% off: Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. Three bottles is also close to a full titration-and-maintenance supply, so it’s how committed users actually buy.

Sources

• PMIDs 37366315 (NEJM Phase 2 obesity), 37385280 (Lancet Phase 2 T2D, dulaglutide comparator), 38858523 (Nat Med MASLD; PMC11271400), 40685589, 39305981, 39761578, 40291085, 41054801, 41056349.
• confirms the T2D comparator was dulaglutide (not metformin) and flags the misattributed “SURMOUNT = retatrutide” / “daily → 137% more AEs” claims (SURMOUNT is a tirzepatide program) as not supported — none of those claims appear in this article.
• Voy, HCPLive, Nature Medicine PMC, Lilly TRIUMPH-4 release.
• (lots RET750, RET602).
• Video digests: Williams masterclass (2026-06-03), Froese side-effects (2026-06-03), one practitioner masterclass (2026-06-01), Jones Reta/GHK/MOTS stack (2026-06-03), Hedayat pathologist explainer (2026-06-07) — (triple-lock mechanism, SA-node HR mechanism, anhedonia/nucleus-accumbens, 80%+ liver-fat framing, supply-chain “Russian Roulette”).
• Phase 3 TRIUMPH topline (2026-06-07 fact-check, vs full publications): Eli Lilly investor releases + AJMC / Pharmacy Times / BioPharma Dive coverage — TRIUMPH-1 (−28.3% at 80 wk, −30.3% at 104 wk in BMI ≥35, 45.3% ≥30%; May 2026) and TRIUMPH-4 (−28.7% at 68 wk; Dec 2025).
• TRIUMPH-4 knee-OA result (verified): trial-design paper Giblin et al., Diabetes Obes Metab 2026;28(1):83–93 — PMID 41090431, DOI 10.1111/dom.70209, PMC12673447, NCT05931367; topline pain/function efficacy via Lilly press release + medical-press coverage. Phase 2 obesity anchor confirmed: Jastreboff 2023 NEJM, DOI 10.1056/NEJMoa2301972, NCT04881760, PMID 37366315.

Cross-links: Tesamorelin · NAD+ · MOTS-c · Ipamorelin · Wolverine (BPC-157 + TB-500).